Objectives: To investigate the occurrence and characteristics of extended-spectrum b-lactamase (ESBL)-and AmpC-producing Enterobacteriaceae isolates in clinical samples of companion animals and horses and compare the results with ESBL/AmpC-producing isolates described in humans.
Introduction
Members of the family Enterobacteriaceae commonly express plasmid-encoded broad-spectrum b-lactamases (TEM-1, TEM-2 and SHV-1) that confer resistance to amino-penicillins and firstgeneration cephalosporins, but not to third-and fourthgeneration cephalosporins. The introduction of third-generation cephalosporins in the 1980s was a milestone in antimicrobial chemotherapy and improved the treatment options in human and veterinary medicine. 1 Unfortunately, resistance to extendedspectrum cephalosporins (ESCs) emerged a few years later. Resistance to ESCs in Enterobacteriaceae is most often related to the production of extended-spectrum b-lactamases (ESBLs) or AmpC b-lactamases. ESBLs confer resistance to aminopenicillins, cephalosporins and monobactams and are inhibited by clavulanic acid. AmpC b-lactamases have a broader spectrum of resistance, including the cephamycins, and are not inhibited by b-lactamase inhibitors. The production of ESBLs and AmpC b-lactamases is often plasmid mediated. Moreover, these plasmids frequently carry genes encoding resistance to other drug classes, such as fluoroquinolones, aminoglycosides, sulfaderivatives and trimethoprim. 2, 3 Therefore treatment options for infections caused by ESBL-and/or AmpC-producing organisms are limited. Initially these organisms were associated with hospitals and institutional care in humans, but they are now increasingly found in the community and in food-producing animals, particularly poultry, suggesting an exchange of organisms or genes between the different reservoirs, or a different antibiotic use behaviour. 4 In the Netherlands, ESCs are authorized for use in food-producing animals (ceftiofur, cefquinome) and companion animals (cefovecin). Resistance to ESCs has been studied in detail in Gram-negative bacteria isolated from humans and food-producing animals. 5, 6 However, data on ESBL-and AmpC b-lactamase-producing Enterobacteriaceae in companion animals and horses are limited. 7 The objective of this study was to investigate the occurrence of ESBL/AmpCproducing organisms in clinical samples, to further characterize these isolates and to compare the results with ESBL-and AmpCproducing isolates described in humans.
Materials and methods

Bacterial isolates
The Veterinary Microbiological Diagnostic Center (VMDC) of Utrecht University investigates samples from all over the Netherlands. Per year approximately 10 000 samples are submitted for bacteriological analysis and about 48% of these samples originate from dogs, 18% from cats, 12% from horses, 10% from food-producing animals and 12% from other animals including reptiles, birds and mammals other than those mentioned. From October 2007 to August 2009, 10755 isolates, derived from approximately 18 000 samples, of which 2700 were Enterobacteriaceae, were tested for susceptibility to a wide range of antimicrobial agents by disc diffusion using a semi-confluent inoculum of the bacteria on Iso-Sensitest agar (bioTRADING, Mijdrecht, The Netherlands) with Neo-Sensitabs (Rosco Diagnostica, Taastrup, Denmark). Species were identified by conventional biochemical methods. Salmonella serovar identification was performed using microtitre and slide agglutination methods (O-and H-group antigens) according to the latest version of the Kauffman-White scheme. All Enterobacteriaceae isolates that displayed an inhibition zone ≤25 mm for ceftiofur (dog/cat/turtle isolates) and/or cefquinome (horse isolates) were included in the study and stored at 2808C until further analysis.
Phenotypic ESBL/AmpC testing
The isolates were tested phenotypically for ESBL production by combination disc tests using cefotaxime and ceftazidime with and without clavulanic acid (Becton Dickinson) according to CLSI guidelines. 8 In addition, a cefoxitin disc (30 mg, Becton Dickinson) was added to this test, to detect AmpC phenotypes. All isolates classified as intermediate or resistant using CLSI criteria (≤17 mm) to cefoxitin were suspected to be AmpC producers.
Escherichia coli genotyping
In order to compare the genotypes of the E. coli isolates found in this study with ESBL-producing E. coli in former human studies, all E. coli strains were genotyped by multilocus sequence typing (MLST) as described previously. 9 Sequences were uploaded on the MLST web site (http://mlst.ucc.ie/). 
Susceptibility testing
Isolates were classified as resistant based on EUCAST clinical breakpoints (www.eucast.org) and, if not available (for sulfamethoxazole and tetracycline), CLSI clinical breakpoints. 8 Serratia marcescens is intrinsically resistant to colistin and Proteus mirabilis to both colistin and tetracycline. 10 These bacterial species were not included to calculate multiresistance.
b-Lactamase identification
All isolates were screened for bla SHV , bla LEN , bla TEM , bla OXA , bla CTX-M , bla DHA , bla ACC , bla MOX , bla FOX or bla CMY gene families by miniaturized microarray (Identibac, AMR-ve 05 genotyping, Alere International, Tilburg, The Netherlands). 11 The gene families that responded positively in the array were further typed by PCR and sequencing using primers displayed in Table 1 . PCR consisted of 30 cycles (30 s of denaturation at 948C, 30 s of annealing at temperatures mentioned in Table 1 and 60 s of extension at 728C) after one step of 5 min at 948C. Amplicons were purified and sequenced as described previously. 5 All E. coli isolates with AmpC phenotypes that could not be attributed to the presence of a plasmid-mediated AmpC gene were tested for mutations in the ampC promoter/attenuator region as described previously. 12 PCRs to detect bla SHV , bla CTX-M or bla TEM genes were performed in isolates with an ESBL phenotype in which the array was negative for probes encoding ESBL gene families (Table 1) .
Additional resistance gene identification
Antibiotic resistance genes were detected using the same microarray that was used for the screening of b-lactamase genes. This array included probes for 40 non-b-lactam resistance gene families known to occur in Gram-negative bacteria. 11 Isolates with positive signals for qnr genes, which encode for plasmid-mediated quinolone resistance genes, were further analysed by PCR and sequencing using primers for qnrA, qnrB and qnrS as displayed in Table 1 and as described previously.
in their samples only when initial antibiotic treatment fails, the isolates obtained are considered to be derived from animals that have received one or more antibiotic treatments. The isolates were cultured from urine (n¼ 32), wound (n¼ 15), peritoneal fluid (n ¼5), uterus (n¼ 5), trachea (n¼ 3), blood (n¼ 2), faeces (n¼ 1), bile (n¼ 1) and a throat sample (n¼ 1). Most isolates were E. coli (n¼ 48). Other isolates were identified as Enterobacter cloacae (n¼11), P. mirabilis (n¼ 3), Salmonella enterica subspecies enterica 4, [5] ,12:b:2 (n¼1), S. marcescens (n¼ 1) and Citrobacter freundii (n¼ 1).
Combination disc tests resulted in 29 isolates displaying an ESBL phenotype, 22 an AmpC phenotype, 6 a mixed ESBL/ AmpC phenotype (displaying synergy with clavulanic acid and resistance to cefoxitin) and 2 displayed inconclusive results in the confirmation test (resistant to cefotaxime and/or ceftazidime, but no synergy with clavulanic acid and susceptible to cefoxitin). This was designated to be an inhibitor-resistant ESBL (IRE) type. In the remaining six isolates (four from dogs and two from cats), although with inhibition zones of ≤25 mm for ceftiofur, the ESBL phenotypic test was negative. These six isolates had MICs between ≤0.06 and 0.5 mg/L for cefotaxime and between ≤0.25 and 0.5 mg/L for ceftazidime, and molecular analysis of these isolates did not result in the detection of an ESBL and/or AmpC gene. The isolates that showed either an ESBL, ESBL/ AmpC or IRE type were all resistant to cefotaxime (MIC .2 mg/ L) and/or ceftazidime (MIC .4 mg/L). Four isolates displaying an AmpC phenotype had cefotaxime and ceftazidime MIC values below the clinical breakpoints. In sum, of 2700 isolates screened, 55 isolates (2.0%) were resistant to either cefotaxime or ceftazidime.
In the 29 isolates with an ESBL phenotype the following ESBL genes were found: bla CTX-M-1 (n¼17), bla CTX-M-15 (n¼ 4), bla CTX-M-14 (n¼ 1), bla CTX-M-2 (n¼ 2), bla TEM-52 (n¼ 3) and a combination of bla CTX-M-1 and bla CTX-M-14 (n¼ 1). In one isolate no ESBL gene could be detected (Table 2) . No bla SHV or bla OXA genes encoding for ESBL production were detected. and one of these isolates (a P. mirabilis with bla CMY-2 ) was clinically susceptible to cefotaxime and ceftazidime (Table S1 , available as Supplementary data at JAC Online). Four isolates with an AmpC phenotype had mutations in the promoter region of the chromosomal ampC gene. These four isolates had mutations in the ampC gene promoter belonging to sequence types (STs) 2, 3 (n¼ 2) and 31 as described by Mulvey et al.
14 Two of those isolates (one with type 2 and one with type 3) were clinically susceptible to cefotaxime and ceftazidime (Table S1 ). The remaining seven isolates displaying an AmpC phenotype all belonged to E. cloacae. In these isolates no plasmid-mediated AmpC gene was detected with the methods used (Tables 2  and S1 ). One isolate of this group had MICs of 1 mg/L and 0.5 mg/L for cefotaxime and ceftazidime, respectively.
Among the isolates showing a combined ESBL/AmpC phenotype, bla CTX-M-9 (n¼ 4, all E. cloacae), bla CTX-M-14 in combination with type 4 mutations in the ampC attenuator region 14 (n¼ 1) and a combination of bla CTX-M-15 and bla CMY-2 were detected (n¼ 1) (Tables 2 and S1 ).
Among the two isolates with inconclusive results in the combination disc test (IRE), one carried bla TEM-30 and in the other isolate (S. marcescens) no ESBL or AmpC genes were observed (Table 2) .
Most isolates were multidrug resistant: 74% of all 61 isolates included in the calculation (all isolates, except P. mirabilis and S. marcescens) were resistant to three or more antimicrobial classes, and 32% were resistant to more than five classes of antibiotics. Among the isolates included in this calculation, nine were clinically susceptible to cefotaxime and/or ceftazidime, six of these were resistant to three or more antibiotics and one of them was resistant to more than five antibiotics. Besides b-lactamase genes, the following gene families were observed, encoding resistance to trimethoprim [dfrA1 (23%), dfrA12 (5%), dfrA14 (3%), dfrA17 (25%), dfrA19 (2%), dfrV (6%)], sulphonamides [sul1(42%), sul2 (12%), sul3 (2%)], fluoroquinolones [qnr (detects qnrA genes, 6%), qnrB (2%), qnrS (3%)], tetracyclines [tetA (6%), tetB (25%), tetC (2%)], aminoglycosides [aadA1 (29%), aadA2 (17%), aadA4 (14%), aac(6 ′ )-Ib (8%), strA (3%), strB (25%), ant2a (8%)], chloramphenicol [cmlA1 (3%), catA1 (25%), catB3 (2%)], florfenicol [floR (5%)] and macrolides [ermB (3%), ereA (3%), ereB (20%)]. In addition, integrase genes intI1 (29%) and intI2 (3%) were found (Table S1 ). PCR and sequencing of the seven isolates positive for a qnr gene in the array demonstrated the presence of three qnrA1 genes; all three were detected in E. cloacae isolates from dogs also carrying bla CTX-M-9 . Two qnrS1/S3 genes (no distinction could be made between qnrS1 and qnrS3 with the primers used) were observed in E. cloacae carrying bla TEM-1 isolated from cats and one qnrB17 variant (qnrB17 with one silent mutation at position 169 GCG GCA) was found in C. freundii carrying bla CMY-39 isolated from a turtle. In one isolate (ID 32, Table S1 ), although positive for the qnr probe in the array, no qnr PCR product could be amplified with the primers used in this study (Table 1) . This strain was susceptible to ciprofloxacin (MIC 0.015 mg/L) as well as to nalidixic acid (MIC ≤4 mg/L) (Table S1 ), confirming the absence of a qnr gene.
MLST of the E. coli isolates resulted in 28 different STs ( Table 2 ). The predominant STs were ST88 (n¼ 6), ST162 (n¼ 3), Table 2 . Chromosomal ampC types refer to mutations in the chromosomal ampC gene as described by Mulvey et al.
14 ST58 (n¼ 3), ST34 (n¼ 3) and ST156 (n¼ 3). Three new STs were identified: ST2225, ST2226 and ST2227. Except for the two isolates from the horses owned by the same person, which both belonged to ST34, no relation was found between STs and the area where the animals lived, or where the isolates were collected (data not shown).
Discussion
A prevalence of 2% ESC resistance in clinical isolates derived from companion animals is comparable to what is found in other countries. 15, 16 In this study we used ceftiofur or cefquinome to detect resistance to ESCs. Veterinary diagnostic laboratories often use cephalosporins that are commonly used in veterinary practice to perform susceptibility tests. However, these antibiotics have been shown to be less suitable as indicator cephalosporins for isolates with ESBL or plasmid-mediated AmpC b-lactamases. 17 In our study, screening with these cephalosporins using non-standardized interpretive criteria resulted in 19 (29%) apparently false-positive isolates, in which no ESBL and/ or plasmid-mediated AmpC genes could be detected by array or PCR and sequencing. Six of these (all E. coli) were negative in the phenotypic confirmation test and had MICs below clinical breakpoints for cefotaxime and ceftazidime. Four other isolates (two E. coli, one P. mirabilis and one E. cloacae), although displaying an AmpC phenotype, also had MICs below the clinical breakpoints for both ESCs. This resulted in a misclassification of 15% (10/65) of the isolates being resistant to ESCs using ≤25 mm as cut-off value for ceftiofur or cefquinome in the disc diffusion test with Neo-Sensitabs (Rosco). To have fewer false-positive results in the future both the method and the interpretative criteria should be critically analysed and possibly reconsidered.
Overall a variety of ESBL genes was found within six bacterial species isolated from four animal species. bla CTX-M-1 was the predominant ESC resistance gene found (26%). This gene was also the predominant ESBL gene among Enterobacteriaceae studied in Dutch horses in 2003 -05. 18 At that time, only bla CTX-M-1 was isolated. Our study shows that in later years bla CTX-M-2 and bla CTX-M-14 also occurred in Enterobacteriaceae from Dutch horses.
bla CTX-M-1 was recently described as the predominant ESBL gene in cefotaxime-resistant E. coli and S. enterica isolates (49%) of Dutch poultry 5 and in poultry meat isolates (49%) derived from Dutch supermarkets. 6 In Dutch patients, bla CTX-M-1 was not predominant in clinical infections (21%-24%), 6, 19 but it was the predominant gene (46%) found in ESC-resistant E. coli derived from rectal swabs of human patients in Dutch hospitals. 19 Our results show that bla CTX-M-1 was present among others in E. coli ST117 (n ¼2), ST58 (n¼ 3) and ST162 (n¼ 3). These E. coli genotypes are described in Dutch poultry (ST117 and ST58) and patients (ST117, ST58 and ST162) carrying bla CTX-M-1 . 6 This suggests a clonal spread of these E. coli genotypes carrying bla CTX-M-1 between different hosts.
A remarkable finding in our study was that all bla CTX-M-9 genes (n¼ 4) occurred in E. cloacae isolates, three derived from dogs and one from a cat. The canine isolates also harboured the plasmid-mediated quinolone resistance gene qnrA1. The combined presence of bla CTX-M-9 and qnrA1 has been described in outbreak strains of Enterobacter hormaechei (initially also classified as E. cloacae) in a Dutch hospital at Utrecht University Medical Centre carrying a conjugative plasmid pQC of the IncHI2 family with several complex integrons containing aadB, bla CTX-M-9 and qnrA1. 20, 21 The three canine isolates were not screened for the aadB gene, but had non-wild-type MICs of gentamicin, and two isolates contained a class 1 integron. To our knowledge this has not been reported previously in clinical isolates from dogs. The dogs and their owners originated from three different areas in the Netherlands and none of them originated from the area around Utrecht, which confirms the observed nationwide outbreak of qnrA1-positive multidrug-resistant E. cloacae in human patients. 22 Moreover, in 2008 an incHI2 plasmid containing qnrA1 and bla CTX-M-9 was found in Salmonella Paratyphi B var. Java isolated from broilers.
23, 24 Together with our data this suggests that a plasmid with this combination of resistance genes is not only present in different areas within the Netherlands, but has also disseminated in different hosts, including humans, foodproducing animals and companion animals.
Another interesting finding in our study was the presence of bla CTX-M-15 in different E. coli genotypes. Only one isolate derived from a dog carrying bla CTX-M-15 belonged to uropathogenic E. coli ST131. This ST has emerged globally in hospital and community settings and has been described frequently in humans 25 and incidentally in isolates derived from dogs and horses in several European countries, 25 -27 emphasizing the intraspecies and pan-European spread of this resistant clone. Our data, however, confirm that bla CTX-M-15 in E. coli of dogs is not limited to E. coli ST131, and that other clones like ST88, ST156 and ST648 play a role in the dissemination of this resistance gene as well.
This is the first study providing information about the genes and genotypes involved in ESBL-or AmpC-producing isolates from Dutch companion animals and horses in a large group of isolates. The most prevalent gene found, bla CTX-M-1 , was previously found in Dutch human and poultry isolates. This, together with the presence of the combination of bla CTX-M-9 and qnrA1 in E. cloacae isolates, which was previously described in human isolates, suggests transmission between the different reservoirs or the existence of a common source. The fact that companion animals often live in close contact with their owners makes the occurrence of transmission between them even more likely. This study shows that prudent usage of antibiotics in companion animals and horses should be emphasized and continued susceptibility surveillance to ESCs is recommended.
